Next Generation Sequencing

ZTurnaround time: 3-5 days

Hematology Panels

Comprehensive Myeloid Panel

Our next-generation Comprehensive Myeloid Panel empowers precision in the diagnosis and management of hematologic malignancies by consolidating multiple complex assays into one streamlined test. Designed for maximum clinical impact, this assay delivers broad and actionable genomic insight into the key drivers of myeloid disease.

With an expanded total of 81 genes (52 DNA mutation genes and 29 RNA fusion genes) the panel enables highly sensitive detection of single nucleotide variants, insertions/deletions, and fusion transcripts with a limit of detection as low as 3%. This integrated approach accelerates turnaround time, enhances workflow efficiency, and provides deeper molecular clarity to guide treatment decisions.

Applications include:

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Myeloproliferative Neoplasms (MPN)
• Chronic Myeloid Leukemia (CML)
• Chronic Myelomonocytic Leukemia (CMML)

Comprehensive Lymphoid Panel

Our lymphoid NGS panel delivers comprehensive profiling across 66 lymphoma-associated genes. This design enables sensitive detection of clinically significant mutations, insertions/deletions, and splice-site variants with a variant allele frequency (VAF) threshold of 3%.

The panel addresses the complexity and heterogeneity of lymphoid neoplasms in a single, streamlined assay, eliminating the need for multiple sequential tests. It provides broad molecular insights that support diagnosis, prognostic stratification, and therapeutic decision-making, while also aligning with NCCN and WHO guidelines.

Diseases covered include:

• Chronic Lymphocytic Leukemia (CLL)
• Marginal Zone Lymphoma
• Lymphoplasmacytic Lymphoma (LPL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Hairy Cell Leukemia
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Other Lymphoid Neoplasms

Solid Tumor Panels

Solid Tumor Gene Panel
Our Oncomine Focus Assay (OFA) is a targeted next-generation sequencing (NGS) panel designed to detect the most clinically relevant genomic alterations across a wide range of solid tumors. This assay consolidates multiple testing methods into a single, streamlined workflow, providing fast and comprehensive insights to support precision oncology.
The OFA interrogates 52 key cancer driver genes, covering the most common classes of alterations, including hotspot mutations, copy number variations (CNVs), and gene fusions. This broad profiling allows simultaneous detection of actionable biomarkers with high sensitivity using limited FFPE tissue samples.